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Abstract

Background: Polypharmacy, the simultaneous taking of many medications,
has been well documented and is a topic of much concern for those looking to
improve the quality of care for the elderly. Elderly patients often develop

complicated and multi-factorial health states that require extensive
pharmacotherapy, leaving this population at risk for exposure to drug-drug
interactions and other adverse events. Previous literature supports an association
between an increase in the rate of adverse events as the number of drugs taken by
a patient increases.
Objective: We sought to evaluate the prevalence of polypharmacy, and to
determine patient characteristics that are predictive of exposure to polypharmacy,
in the elderly population of the Emilia-Romagna region in Italy.
Methods: We conducted a retrospective cohort study of the 2007 EmiliaRomagna outpatient pharmacy database linked with patient information available
from a demographic file of approximately 1 million Emilia-Romagna residents
aged ≥65 years. The cohort was comprised of 887 165 elderly subjects who had
at least one prescription filled during the study year. Using the World Health
Organization’s defined daily dose (DDD) to determine the duration of treatment
for a given drug, we defined a polypharmacy episode as overlapping treatment
with five or more medications occurring for at least one day. The prevalence of
polypharmacy was measured together with subject characteristics found to be
predictive of polypharmacy exposure.
Results: A total of 349 689 elderly people in the population (39.4%) were
exposed to at least one episode of polypharmacy during the study period. The
prevalence of polypharmacy substantially increased with age and with a higher
number of chronic conditions. Over 35% of those exposed to polypharmacy were
exposed for 101 or more days of the year. The top three classes of medications
involved in polypharmacy were antithrombotics, peptic ulcer disease and gastrooesophageal reflux disease agents and ACE inhibitors. The odds of exposure to
polypharmacy were higher for older subjects, males and subjects living in urban
areas.
Conclusions: This study provides evidence that the prevalence of
polypharmacy in the elderly in Emilia-Romagna is substantial. Educational
programmes should be developed to inform clinicians about the magnitude of the
polypharmacy phenomenon and the patient characteristics associated with
polypharmacy. Raising physicians’ awareness of polypharmacy may help to
ensure safe, effective and appropriate use of medication in the elderly.

Introduction
Polypharmacy, the simultaneous taking of many medications, has been well
documented in the US and Europe.[1-3] It is a topic of much concern for those
looking to improve the quality of care for the elderly, as patients in this
population often develop complicated and multi-factorial health states. As the
incidence of chronic disease increases, so does the need for pharmacotherapy.[2,4]
This inherently places the elderly at risk of exposure to polypharmacy.
Polypharmacy in the elderly has been correlated with increased age,[2,5] and
with specific diseases, including cardiovascular diseases, rheumatic diseases and
respiratory illnesses.[6] Previous studies have also demonstrated that as the
number of concomitant medications increases in elderly patients, so does the risk
of adverse drug events.[7-9] Furthermore, polypharmacy has been found to be
associated with risk of emergency department visits, hospitalizations, hospital

readmissions and death in the elderly.[7,10,11] The risk of morbidity and mortality
associated with polypharmacy, combined with the trend of population aging
worldwide, makes polypharmacy an area of prime concern and a potential target
for decreasing preventable adverse events.
Despite being a well recognized problem in the elderly population, a
universally accepted, formal definition for polypharmacy has yet to be
established.[1,12] Several studies have categorized polypharmacy into different
levels based on the number of medications taken.[1,2,13-15] More specific
definitions quantify polypharmacy by the number of simultaneous medications
taken by a patient. The definition that is most frequently used is the simultaneous
use of five or more medications. Based on this definition, prevalence estimates
for polypharmacy in the outpatient setting vary from 4% to 42% in the elderly
population.[3-6,16-23]
While polypharmacy in the elderly has been described in several European
countries, the literature on the topic in Italy is scant. The availability of a large,
linkable outpatient pharmacy database in Emilia-Romagna, Italy, a large northern
region with a population of about 4 million inhabitants, provides an excellent
opportunity to evaluate the prevalence of polypharmacy in the elderly and to
determine patient characteristics that are predictive of exposure.

Methods
The study protocol was approved by the Institution Review Board of Thomas
Jefferson University, Philadelphia, Pennsylvania, USA.

Study Design and Population
We conducted a retrospective cohort study of medication use in the elderly
using the Emilia-Romagna outpatient prescriptions database from January 1,
2007 to December 31, 2007. This database includes all medications reimbursed
by the 2007 National Pharmaceutical Formulary (PFN, Prontuario Farmaceutico
Nazionale).1 The characteristics of the database have been described
elsewhere.[24] We linked prescription claims in the pharmacy database with data
from a 2007 demographic file of 960 359 elderly Emilia-Romagna residents
1 The PFN includes all medications marketed in Italy. It has a positive and a
negative drug list, outlining which medicines will be reimbursed and which need
to be paid for in full by patients, respectively. All essential medications, such as
cardiovascular and antihyperglycaemic drugs, are reimbursed by the PFN; nonessential medications such as benzodiazepines, as well as any over-the-counter
medications such as antitussive and cold drugs, are not reimbursed. All Italian
citizens are entitled to access essential healthcare services, including PFNreimbursed medications.

(aged ≥65 years as at January 1, 2007).2 The study cohort was comprised of
887 165 elderly subjects who had at least one prescription filled during the study
year (92.3% of the Emilia-Romagna elderly population).

Study Definitions and Measures
For the purposes of this study we defined polypharmacy as the simultaneous
use of five or more medications, a definition that has been widely used in
previous studies.[3,13,18,19,23,25] Medications were classified using the Anatomical
Therapeutic Chemical (ATC) classification index, and were further differentiated
to the fifth level of classification (e.g. B01AA03 represents warfarin).[26]
Duration of therapy was calculated assuming that daily drug intake was equal to
the defined daily dose (DDD), as determined by the WHO.[26] In addition, it was
assumed that subjects completed the duration of therapy for all filled
prescriptions. Treatment was assumed to have begun on the day that the
prescription was filled. The number of drugs taken on each day of the year was
then calculated for each subject, and occurrence of polypharmacy was tabulated
from this information.
One-year prevalence was defined as the number of individuals who had at least
one episode of polypharmacy during the study period. Subjects exposed to
polypharmacy were also stratified by the total number of days of exposure.
Incidence of polypharmacy was determined using a method previously described
by Bjerrum et al.[13] Subjects with first-time polypharmacy occurrence were
identified for each month. As such, elderly exposed to polypharmacy for the first
time in the final 3 months of 2007 were assumed to represent true incident cases.
The mean monthly first-time occurrence during the final 3 months of 2007 was
assumed to represent the monthly incidence of polypharmacy.

Subject Characteristics
Information on subjects’ age, sex and geographic location was retrieved from
the demographic file. Level of co-morbid disease was calculated using the
Chronic Condition Drug Group (CCDG) score. The CCDG score classifies up to
31 chronic conditions based on consumption of specific medications.[27] The
CCDG score for an individual reflects the extent to which a person is affected by

2 Because of the reimbursement process, information in the Emilia-Romagna
pharmacy database is very accurate. The pharmacy database includes a unique,
anonymous patient identification number, which has been used to link the
pharmacy database with the demographic file. The linkage between the
demographic file and the pharmacy database was virtually complete.

chronic conditions (i.e. higher CCDG scores reflect a higher number of chronic
conditions).

Data Analysis
The unit of analysis for the study was the individual subject. Descriptive
statistics were generated for all variables of interest. A bivariate analysis was
used to compare the characteristics of drug users exposed to polypharmacy and
those not exposed using chi-squared (χ2) tests for categorical variables. A
multivariable logistic regression analysis was used to identify factors that were
predictive of polypharmacy exposure. Subject characteristics that were
incorporated

in

our

model

as

independent

variables

included

sex

(dichotomously), age (categorically) and geographic location (categorically). The
CCDG score was not included in our model because in a separate analysis it was
shown to be correlated with the number of medications a subject received (r =
0.71), and hence inherently correlated with polypharmacy. A p-value <0.05 was
considered significant for all analyses. All data analysis was completed using
SAS® version 9.1 (SAS Institute Inc., Cary, NC, USA).

Results
Subject Characteristics and Medication Use
Of the 887 165 elderly drug users in the region, the mean ± SD age of the study
population was 75.5 ± 7.5 years. Females made up 58.3% of the study population
(table I). The mean ± SD number of distinct medications (i.e. having different
ATC codes) taken during the study period was 6.3 ± 4.2. Total per-patient drug
utilization during the study period was as follows: 39.3% used between one and
four distinct drugs, 28.4% used between five and seven drugs, 17.4% used
between eight and ten drugs, 10.2% used between eleven and fourteen drugs and
4.7% used fifteen or more drugs.
Table I

Prevalence of Polypharmacy
Of the elderly drug users in the region, 349 689 (39.4%) had at least one
episode of polypharmacy exposure during the study period (table I). People
exposed to polypharmacy were more likely to be older male and have a higher
number of co-morbidities. Approximately one-third (36.1%) of elderly exposed
to polypharmacy were prescribed 11 or more distinct medications in the study
period. Of those exposed to polypharmacy, 47.6% were exposed for a total of

≤50 days, 16.8% for 51–100 days, 20.1% for 101–200 days and 15.5% for ≥200
days.
All of the following drug classes were used by more than one-third of subjects
exposed to polypharmacy: antithrombotics; peptic ulcer disease and gastrooesophageal reflux disease agents; ACE inhibitors; antihyperlipidaemic agents;
β-adrenoceptor antagonists; and NSAIDs (table II).
Table II

Incidence of Polypharmacy
Figure 1 shows the number of individuals exposed to polypharmacy for each
month of the study period according to the month in which the first episode of
polypharmacy occurred. The mean monthly occurrence of new exposures to
polypharmacy in the last 3 months of the study period was 11 235. Therefore, the
estimated incidence of subjects exposed for the first time to polypharmacy was
1.3% per month.
Fig. 1

Logistic Regression Analysis
The multivariable logistic regression analysis demonstrated that age, sex and
geographic location were correlated with exposure to polypharmacy (table III).
Using subjects aged 65–74 years as the referent group, risk of exposure to
polypharmacy increased as age increased (odds ratios [OR] 1.76 for age 75–84
years and OR 1.83 for age ≥85 years). The odds of exposure were lower in
females than males (OR 0.85). Finally, there was a slightly lower risk of
polypharmacy exposure for patients in rural areas (hill and mountain locations;
OR 0.98 and 0.96, respectively) than in urban areas (plain location).
Table III

Discussion
To our knowledge, this is the first large, population-based study documenting
the prevalence of polypharmacy in Italy. The evidence generated by this
investigation supports three main conclusions. First, we noted that a large
number of elderly subjects in Emilia-Romagna are exposed to polypharmacy.
Second, we observed that new exposures to polypharmacy occur at a consistent
rate and affect a significant number of elderly subjects. Third, our evidence
demonstrated that a large number of the polypharmacy exposures extend over a
long period of time. Taken as a whole, these findings are cause for concern for

both practitioners and healthcare policy decision makers in Emilia-Romagna
because of the correlation that has been demonstrated between polypharmacy and
inappropriate prescribing in this population.[28] Additional research is needed to
determine if, and to what extent, this phenomenon exists in other regions of Italy.
The data used in our study afford us confidence that the results generated are an
accurate reflection of the patterns of medication use by the elderly in EmiliaRomagna. Other polypharmacy studies frequently rely on pharmacy data
collected upon patient admission to and/or discharge from a hospital,[29] during
patient interactions with data collectors (either at home, over the phone or in an
office setting)[4,5,8,14,30-32] or from patient and/or physician recall,[3] all of which
are methods that leave room for inaccuracies in data collection. Because the
outpatient pharmacy database used in our study was initially collected at the site
of dispensation and was used for reimbursement purposes, the data used in our
study have a much lower likelihood of containing error.
We found the prevalence of polypharmacy in our study cohort of elderly
patients to be 39.4%. This prevalence falls in the high end of the range reported
in previous studies conducted in outpatient settings that used the same definition
of polypharmacy (4–42%).[3,6,16-19,23] While some of the variability in the reported
prevalence among studies is undoubtedly due to variations in clinician practices
and patient behaviours in different countries, it may also be a result of differences
in the sample age,[3,4,16,17] the nature of the data source[3,16-19] and the units of
analysis.[6,18,23] Thus, comparisons between polypharmacy studies can be
extremely cumbersome and difficult to interpret. Despite the challenges faced in
comparing polypharmacy investigations, it is clear that polypharmacy is a
significant problem in the elderly and warrants additional attention. Further
research in this area may help to determine the necessity and most appropriate
mechanism for interventions tailored to the needs of different countries and
populations.
As was expected, our results show that as the number of chronic conditions
increases, so does polypharmacy exposure. Clearly, patients with multiple
chronic conditions must be treated with appropriate pharmacotherapy. For
example, a patient with non-insulin dependent (type II) diabetes mellitus must be
treated with at least one medication, and often multiple medications, to manage
this chronic disease. If this patient also has hypertension and hyperlipidaemia,
then it is quite likely that appropriate treatment of these conditions would result
in exceeding the polypharmacy threshold. For this reason, it is challenging to

determine, based on the number of chronic conditions alone, whether or not the
exposure to polypharmacy is appropriate. Future research exploring how the
presence of chronic conditions affects health outcomes may help uncover when
interventions to address polypharmacy would be beneficial.
Our multivariable analysis showed that older age, male sex and geographic
location were significantly associated with the risk of exposure to polypharmacy.
The correlation between polypharmacy exposure and increased age is supported
by previous literature.[2,5] Our findings reinforce these reports. This association is
of considerable concern because of the implications of overuse of medications in
the elderly. Predisposing factors in the elderly, such as the decline in renal
function that accompanies the aging process,[33] increase the potential for drugdrug and/or drug-disease interactions, drug toxicities and other adverse drug
events.
In our study, males were found to be more likely to be exposed to
polypharmacy. We found only one other study that reported a positive correlation
between male sex and polypharmacy exposure.[34] Conversely, many studies have
reported a correlation between polypharmacy and female sex.[4-6,14,30] Such
discrepancies among study findings could be due to differences in physicians’
prescribing attitude toward sexes, as well as to differences between sexes in
educational and socioeconomic characteristics.[35] Further research exploring the
relationship between sex and polypharmacy is warranted.
Elderly living in urban areas (plain locations) were found to be more likely to
be exposed to polypharmacy than those living in rural areas (hill and mountain
locations). One possible explanation for this result may be that providers
practicing in urban areas differ in their characteristics and, as a result, in their
prescribing patterns. There is evidence that provider attributes, such as sex, and
practice characteristics, including structure and workload, are predictive of
polypharmacy exposure in their patients.[36] However, information on provider
and practice characteristics was not available in our database. Future research
exploring the relationship between polypharmacy and provider characteristics
may be of interest.
The presence of antithrombotics and NSAIDs among the drug categories
commonly used by elderly people exposed to polypharmacy is of great concern
because of the potential for adverse drug events with these agents.
Antithrombotics such as warfarin have a narrow therapeutic window and a high
number of drug-drug interactions that put these patients at risk.[37,38] In addition,

NSAIDs are found on published lists of medications to be avoided in the elderly
because of the high number of NSAID related adverse events and potential drug
interactions in this population.[28,39,40]
Several of the medication classes that were identified as commonly used by
patients exposed to polypharmacy in our study have also been reported in
previous investigations.[2,5,6,8,22] Bjerrum et al.[6] reported that elderly patients
exposed to polypharmacy frequently used cardiac therapies and analgesics
(including NSAIDs). Flaherty et al.[8] reported that gastrointestinal agents and
ACE inhibitors were among the most frequently used medications in a cohort of
older patients discharged from a home care agency. Knowledge of medication
classes that are commonly part of polypharmacy regimens may assist physicians
in identifying elderly patients for whom particular attention should be paid when
reviewing the appropriateness, safety and efficacy of their drug therapy.

Limitations
Our study has several limitations. First, we cannot say with certainty whether or
not prescribed medicines were actually used by patients. Next, we used DDDs to
estimate the duration of therapy for each prescription in order to determine
overlapping of treatments and therefore identify polypharmacy exposures. The
WHO Collaborative Centre for Drug Statistics and Methodology defines the
DDD as “the assumed average maintenance dose per day for a drug used for its
main indication in adults.”[41] DDD is a useful estimator for calculating durations
of treatment.[42] However, substantial differences may exist between the doses
determined using DDDs and the actual prescribed dose. This may be particularly
true for drugs such as antithrombotics, which require individualized dosing for
each patient because of the narrow therapeutic window. In addition, the elderly
may require more frequent dosage adjustments because of issues such as renal
and hepatic impairment. Because each prescription is tailored to the patient’s age,
sex, weight and other factors that may affect the drug’s pharmacokinetics and
pharmacological activity, DDDs provides only a rough estimate of the duration
of therapy. It is possible that some misclassification of polypharmacy occurred,
but this is not likely to have substantially impacted our results.
The Emilia-Romagna database does not include prescription medications not
reimbursed by the PFN, such as benzodiazepines, or any non-prescription
medications such as over-the-counter medications, herbal remedies or dietary
supplements. A correlation between non-prescription medication use and
polypharmacy in the elderly has been reported in the literature.[3] These
treatments also carry the risk of interactions and adverse events,[43-46] and

therefore are relevant in the discussion of polypharmacy. For these reasons, it is
reasonable to conclude that our results are a conservative estimate of the true
prevalence of polypharmacy in Emilia-Romagna.
The use of CCDG scores as a proxy for patient co-morbidities is a viable
method but has its limitations. There are some diseases that have no
pharmacological treatment and are therefore not accounted for in the CCDG
score. In addition, many medications may be used for the treatment of more than
one disease. It may therefore be impossible to differentiate whether the use of
one medication, in a patient taking multiple medications, is for the treatment of a
separate co-morbidity or is part of a multi-drug regimen for a single disease.
While it is not possible for us to know whether we more frequently overestimated or under-estimated the CCDG scores, it is likely that these errors
cancelled each other out in the aggregate.

Conclusions
Our study results add to the growing evidence that a significant proportion of
the elderly are exposed to polypharmacy. However, it is important to emphasize
that polypharmacy is not synonymous with inappropriate treatment. Many elderly
patients who are taking more than five medications may have appropriate
indications for all of these therapies and may lack any major risk for adverse
events, such as drug-drug or drug-disease interactions. However, the risk of these
adverse events increases as the number of medications that a patient takes
simultaneously increases. Therefore, it is highly desirable that physicians identify
and keep under surveillance patients exposed to polypharmacy. Raising
awareness of the characteristics of those elderly most likely to be exposed to
polypharmacy, in conjunction with studies describing the risks associated with
increased medication use in this population, may help to ensure safe, effective
and appropriate use of medication in the elderly.
In summary, our analysis found that the prevalence of polypharmacy exposure
in the elderly population of Emilia-Romagna is of great magnitude. Several
factors that may be used to screen patients for risk of polypharmacy exposure
were identified. This study provides clinicians in the region with information that
they may use to improve the quality of care provided to their elderly patients.
Acknowledgements

This research was supported through a collaborative agreement between the
Regional Health Care Agency, Assessorato alla Sanita’, Emilia-Romagna, Italy
and Thomas Jefferson University, Philadelphia, PA, USA. Dr. Slabaugh and Dr.
Abouzaid are enrolled in a fellowship in pharmacoeconomics and outcomes
research sponsored by Ortho-McNeil-Janssen Scientific Affairs, LLC, Titusville,
NJ, USA. Dr. Maio had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of data analysis. The
authors have no conflicts of interests relevant to this research. We thank Roberto
Grilli, MD and Rossana De Palma, MD from the Regional Health Care Agency,
Emilia-Romagna, Italy, for providing the data and guidance.

References
[1] Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am
Acad Nurse Pract 2005 Apr; 17 (4): 123-32
[2] Jyrkka J, Vartiainen L, Hartikainen S, et al. Increasing use of medicines in
elderly persons: a five-year follow-up of the Kuopio 75+ study. Eur J Clin
Pharmacol 2006 Feb; 62 (2): 151-8
[3] Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors
of polypharmacy among older primary care patients in Germany. Fam Pract 2007
Feb; 24 (1): 14-9
[4] Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication
use in the ambulatory adult population of the United States: the Slone survey.
JAMA 2002 Jan 16; 287 (3): 337-44
[5] Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and
polypharmacy are increasing among the elderly. J Clin Epidemiol 2002 Aug; 55
(8): 809-17
[6] Bjerrum L, Sogaard J, Hallas J, et al. Polypharmacy: correlations with sex,
age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998
May; 54 (3): 197-202
[7] Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of
hospital admissions: results from the Italian Group of Pharmacoepidemiology in
the Elderly (GIFA). J Am Geriatr Soc 2002 Dec; 50 (12): 1962-8
[8] Flaherty JH, Perry 3rd HM, Lynchard GS, et al. Polypharmacy and
hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci
2000 Oct; 55 (10): M554-9
[9] Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events
among older adults in the ambulatory setting. J Am Geriatr Soc 2004 Aug; 52
(8): 1349-54
[10] Alarcon T, Barcena A, Gonzalez-Montalvo JI, et al. Factors predictive of
outcome on admission to an acute geriatric ward. Age Ageing 1999 Sep; 28 (5):
429-32
[11] Mannesse CK, Derkx FH, de Ridder MA, et al. Contribution of adverse
drug reactions to hospital admission of older patients. Age Ageing 2000 Jan; 29
(1): 35-9

[12] Viktil KK, Blix HS, Moger TA, et al. Polypharmacy as commonly defined
is an indicator of limited value in the assessment of drug-related problems. Br J
Clin Pharmacol 2007 Feb; 63 (2): 187-95
[13] Bjerrum L, Rosholm JU, Hallas J, et al. Methods for estimating the
occurrence of polypharmacy by means of a prescription database. Eur J Clin
Pharmacol 1997; 53 (1): 7-11
[14] Jyrkka J, Enlund H, Korhonen MJ, et al. Patterns of drug use and factors
associated with polypharmacy and excessive polypharmacy in elderly persons:
results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging 2009;
26 (6): 493-503
[15] Haider SI, Johnell K, Weitoft GR, et al. The influence of educational level
on polypharmacy and inappropriate drug use: a register-based study of more than
600,000 older people. J Am Geriatr Soc 2009 Jan; 57 (1): 62-9
[16] Haider SI, Johnell K, Thorslund M, et al. Analysis of the association
between polypharmacy and socioeconomic position among elderly aged > or =77
years in Sweden. Clin Ther 2008 Feb; 30 (2): 419-27
[17] Thomas HF, Sweetnam PM, Janchawee B, et al. Polypharmacy among
older men in South Wales. Eur J Clin Pharmacol 1999 Jul; 55 (5): 411-5
[18] Kennerfalk A, Ruigomez A, Wallander MA, et al. Geriatric drug therapy
and healthcare utilization in the United Kingdom. Ann Pharmacother 2002 May;
36 (5): 797-803
[19] Chen YF, Dewey ME, Avery AJ. Self-reported medication use for older
people in England and Wales. J Clin Pharm Ther 2001 Apr; 26 (2): 129-40
[20] Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, et al. The development of
polypharmacy: a longitudinal study. Fam Pract 2000; 17 (3): 261-7
[21] Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an
independent risk factor for adverse drug events in an elderly outpatient
population? Am J Geriatr Pharmacother 2007 Mar; 5 (1): 31-9
[22] Jörgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use,
diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;
35 (9): 1004-9
[23] Grimmsmann T, Himmel W. Polypharmacy in primary care practices: an
analysis using a large health insurance database. Pharmacoepidemiol Drug Saf
2009 Dec; 18 (12): 1206-13
[24] Louis DS, Yuen EJ, Maio V, et al. A population-based longitudinal
healthcare database in the Emilia-Romagna region, Italy: a resource for planning
and research. Health Policy Newsl 2005 June; 18 (2): 6
[25] Haider SI, Johnell K, Thorslund M, et al. Trends in polypharmacy and
potential drug-drug interactions across educational groups in elderly patients in
Sweden for the period 1992-2002. Int J Clin Pharmacol Ther 2007 Dec; 45 (12):
643-53
[26] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD
Index 2009 [online]. Available from URL: http://www.whocc.no/atcddd/
[Accessed 2009 Sep 28]
[27] Maio V, Yuen E, Rabinowitz C, et al. Using pharmacy data to identify
those with chronic conditions in Emilia Romagna, Italy. J Health Serv Res Policy
2005 Oct; 10 (4): 232-8
[28] Maio V, Yuen EJ, Novielli K, et al. Potentially inappropriate medication
prescribing for elderly outpatients in Emilia Romagna, Italy: a population-based
cohort study. Drugs Aging 2006; 23 (11): 915-24

[29] Corsonello A, Pedone C, Corica F, et al. Polypharmacy in elderly patients
at discharge from the acute care hospital. Ther Clin Risk Manag 2007; 3 (1):
197-203
[30] Rozenfeld S, Fonseca MJ, Acurcio FA. Drug utilization and polypharmacy
among the elderly: a survey in Rio de Janeiro City, Brazil. Rev Panam Salud
Publica 2008 Jan; 23 (1): 34-43
[31] Steinman MA, Seth Landefeld C, Rosenthal GE, et al. Polypharmacy and
prescribing quality in older people. J Am Geriatr Soc 2006; 54 (10): 1516-23
[32] Ziere G, Dieleman JP, Hofman A, et al. Polypharmacy and falls in the
middle age and elderly population. Br J Clin Pharmacol 2006 Feb; 61 (2): 21823
[33] Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine
clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976 Mar;

31 (2): 155-63
[34] Chan DC, Hao YT, Wu SC. Polypharmacy among disabled Taiwanese
elderly: a longitudinal observational study. Drugs Aging 2009; 26 (4): 345-54
[35] Bierman AS, Pugh MJ, Dhalla I, et al. Sex differences in inappropriate
prescribing among elderly veterans. Am J Geriatr Pharmacother 2007 Jun; 5 (2):
147-61
[36] Bjerrum L, Sogaard J, Hallas J, et al. Polypharmacy in general practice:
differences between practitioners. Br J Gen Pract 1999 Mar; 49 (440): 195-8
[37] Jonsson AK, Spigset O, Jacobsson I, et al. Cerebral haemorrhage induced
by warfarin: the influence of drug-drug interactions. Pharmacoepidemiol Drug
Saf 2007 Mar; 16 (3): 309-15
[38] Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential
drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther
2008 Apr; 33 (2): 141-51
[39] Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for
potentially inappropriate medication use in older adults: results of a US
consensus panel of experts. Arch Intern Med 2003 Dec 8-22; 163 (22): 2716-24
[40] Maio V, Del Canale S, Abouzaid S. Using explicit criteria to evaluate the
quality of prescribing in elderly Italian outpatients: a cohort study. J Clin Pharm
Ther 2010; 35 (2): 219-29
[41] WHO Collaborating Centre for Drug Statistics Methodology. DDD
definition and general considerations [online]. Available from URL:
http://www.whocc.no/ddd/definition_and_general_considera/ [Accessed 2010
Aug 02]
[42] Merlo J, Wessling A, Melander A. Comparison of dose standard units for
drug utilisation studies. Eur J Clin Pharmacol 1996; 50 (1-2): 27-30
[43] Abebe W. Herbal medication: potential for adverse interactions with
analgesic drugs. J Clin Pharm Ther 2002 Dec; 27 (6): 391-401
[44] Bush TM, Rayburn KS, Holloway SW, et al. Adverse interactions between
herbal and dietary substances and prescription medications: a clinical survey.
Altern Ther Health Med 2007 Mar-Apr; 13 (2): 30-5
[45] Hoblyn JC, Brooks 3rd JO. Herbal supplements in older adults: consider
interactions and adverse events that may result from supplement use. Geriatrics
2005 Feb 22-3; 60 (2): 18-3
[46] Shaw D, Murray V, Volans G. Adverse effects of herbal remedies and OTC
medicines. Br J Clin Pharmacol 1999 Feb; 47 (2): 227-228; author reply: 229-30

Fig. 1. Proportion of subjects exposed to polypharmacy for the first time by
month during 2007. Elderly exposed to polypharmacy for the first time in the
final 3 months of 2007 (see grey bars) were assumed to represent true incident
cases, as per the method described by Bjerrum et al.[13] Thus, the mean monthly
first-time occurrence during the final 3 months of 2007 was assumed to represent
the monthly incidence of polypharmacy.
Table I. Bivariate comparison of characteristics of the patients according to
exposure to polypharmacy
Characteristic
Subjects not exposed to
Subjects exposed to
polypharmacy (n = 537 476)
polypharmacy (n = 349 689)
n
%
n
%
Age (y)*
65–74
294 354
54.8
142 921
40.9
75–84
181 100
33.7
153 227
43.8
≥85
62 022
11.5
53 541
15.3
Sex
Female
318 931
59.3
198 438
56.7
Male
218 545
40.7
151 251
43.3
Geographic location*
Mountain
29 497
5.5
19 140
5.5
(rural)
Hill (rural)
148 786
27.7
96 101
27.5
Plain (urban)
359 193
66.8
234 448
67.0
CCDG score*
0–1
293 485
54.6
20 422
5.8
2–3
230 183
42.8
187 502
53.6
≥4
13 808
2.6
141 765
40.5
No. of drugs prescribed*
1–4
348 405
64.8
5–7
150 670
28.0
101 452
29.0
8–10
32 590
6.1
122 162
34.9
11–14
5 481
1.0
85 042
24.3
≥15
330
0.1
41 033
11.7
CCDG = Chronic Condition Drug Group; * p < 0.05.
Table II. Anatomical Therapeutic Chemical (ATC)[26] level 3 drug classes most
frequently used by subjects exposed to polypharmacy
ATC
Description
Female
Male
All
class
(n =
(n =
(n =
(level 3)
198 438)
151 251)
349 689) [%]
[%]
[%]
B01A
Antithrombotics
65.8
75.9
70.1
A02B
PUD and GERD agents 50.0
46.6
48.5
C09A
ACE inhibitors
34.1
41.9
37.5
C10A
Antihyperlipidaemics
34.8
40.9
37.4
C07A
β-adrenoceptor
35.5
39.0
37.0
antagonists
M01A
NSAIDs
41.3
28.8
35.9
C03C
High-ceiling diuretics
31.7
32.0
31.8
C08C
Selective calcium
29.7
32.1
30.8

channel antagonists
Antidepressants
27.3
15.9
22.4
Vasodilators
18.4
22.9
20.3
Non-adrenergic inhalers 17.1
21.0
18.8
Antihyperglycaemics
17.2
19.8
18.3
(excluding insulin)
C09C
ARBs
18.2
16.5
17.5
C09B
ACE inhibitor
17.0
15.5
16.4
combination products
R03A
Adrenergic inhalers
14.3
18.2
16.0
C09D
ARB combination
17.4
13.0
15.5
products
G04C
BPH products
0.2
32.6
14.2
S01E
Antiglaucoma
12.5
11.2
11.9
preparations and miotics
C01B
Antiarrhythmics, class I
6.7
8.1
7.3
and III
A10A
Insulin and analogues
3.9
4.0
3.9
ARB = angiotensin II type 1 receptor antagonist (angiotensin receptor blocker);
BPH = benign prostatic hyperplasia; GERD = gastro-oesophageal reflux disease;
PUD = peptic ulcer disease.
N06A
C01D
R03B
A10B

Table III. Multivariable logistic regression of patient characteristics associated
with polypharmacy exposure
Characteristic
Odds ratio
95% CI
Age (y)
65–74
1.00
Referent
75–84
1.76
1.74, 1.78*
≥85
1.83
1.80, 1.85*
Sex
Male
1.00
Referent
Female
0.85
0.846, 0.861*
Geographic location
Plain (urban)
1.00
Referent
Hill (rural)
0.98
0.97, 0.98*
Mountain (rural)
0.96
0.94, 0.98*
* p < 0.05 vs referent.

